An American rheumatology fellow explores the differences& similarities between the U.S. & Chinese health systems through a visit toa hospital inHangzhou, China.
Search results for: rituximab
ACR-Led Resolutions Supporting Research Funding, Biosimilars Access Advance at Annual AMA House of Delegates Meeting
An ACR-led resolution that calls for the protection of NIH funding and the ability to negotiate indirect costs will become AMA policy, along with several other resolutions supported by the ACR.
Underwater Biosimilars Coalition Shares Results of Practice Survey with Congressional Leaders
This week, the Coalition sent Congressional leadership a letter detailing the results of a recent survey about how underwater biosimilars are impacting physicians’ ability to provide high-quality care. Almost all of the nearly 200 practices queried reported being underwater on several biosimilars, with rituximab and infliximab biosimilars being the most common.
Large International Study Says Flares Rare After COVID Vaccination
‘Patients with rheumatologic diseases are rightfully concerned about the risk of flares after getting their COVID vaccines, especially after holding immune modulators,’ says says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘A new study is reassuring that flares are rare, even after holding or discontinuing immune modulators.’ The development of a vaccine for…
Flares Rare After COVID Vaccination
The development of a vaccine for COVID-19 changed the course of the pandemic; however, it also raised questions about whether to withhold or reduce immunosuppressive therapies and other medications for patients with inflammatory, rheumatic and musculoskeletal disease (IRMD), note the authors of a new study published in Annals of the Rheumatic Diseases. An argument for…
Experts Discuss Guidelines for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disease
Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Scleroderma Program, notes that more recent studies have increased our awareness…
Cancer & RA Drugs: Are Some Drugs Riskier than Others?
Sendaydiego et al. asked: Do some DMARDs pose a greater cancer risk than others for patients with RA? Here are insights from the study and its clinical implications.
Strong Argument: Recent Developments in Myositis Diagnosis & Care
Lisa Christopher-Stine, MD, MPH, discussed the latest findings on myositis and its subtypes, including insights into antibodies linked to cancer and treatments for these patients.
Skin Matters: The Intersection of Dermatology & Rheumatology
Jun Kang, MD, addressed the intersection of dermatology and rheumatology, describing the nuance necessary to accurately evaluate skin manifestations and differentiate multiple conditions.
Case Report: Uncommon Complications in ANCA-Associated Vasculitis
Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis is a rare autoimmune condition characterized by inflammation of small- and medium-sized vessels. ANCA-associated vasculitis can lead to multisystem organ complications, including life-threatening pulmonary hemorrhage, renal failure and death. We present a case of ANCA-associated vasculitis complicated by complement-mediated thrombotic microangiopathy (c-TMA). Of the rheumatic diseases, systemic lupus erythematosus…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 47
- Next Page »